Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells 400 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director owned 603 shares in the company, valued at approximately $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded up $0.99 on Wednesday, hitting $797.99. The company’s stock had a trading volume of 571,786 shares, compared to its average volume of 859,210. The company has a market capitalization of $82.16 billion, a PE ratio of 19.72, a PEG ratio of 1.37 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The company has a 50 day moving average price of $665.31 and a 200 day moving average price of $713.04. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $12.81 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently bought and sold shares of REGN. Brighton Jones LLC grew its stake in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $226,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $3,183,000. Gabelli Funds LLC increased its stake in shares of Regeneron Pharmaceuticals by 3.0% in the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after acquiring an additional 55 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in Regeneron Pharmaceuticals by 18.8% during the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after acquiring an additional 5,120 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on REGN. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Leerink Partners reaffirmed a “market perform” rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. Canaccord Genuity Group decreased their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Finally, JPMorgan Chase & Co. dropped their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $797.75.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron’s Eylea HD and Dupixent franchises continue to support growth, while oncology products and pipeline progress provide additional catalysts. The company’s shares were described as having risen 21.9% over the past month. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
• Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, signaling continued confidence in the company’s outlook despite recent clinical and legal concerns. Goldman Sachs Keeps Their Buy Rating on Regeneron
• Neutral Sentiment: Multiple law firms repeated notices that investors have until September 14, 2026 to seek lead-plaintiff status in a securities class action. The announcements largely repeat the same lawsuit rather than disclose a new company development. Regeneron Class Action Lawsuit Notice
• Negative Sentiment: The litigation stems from allegations that Regeneron misled investors about the viability of its Phase 3 Fianlimab-Libtayo trial for advanced melanoma. The trial’s failure reportedly erased approximately $11 billion in market value, increasing legal and reputational risk. REGN Stockholders Class Action Notice

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.